Clinical Research Directory
Browse clinical research sites, groups, and studies.
PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers
Sponsor: JW Pharmaceutical
Summary
A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and C2406 in Healthy Volunteers
Official title: An Open-label, Crossover, Phase 1 Clinical Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Drug-drug Interactions and Safety/Tolerability of Epaminurad and C2406 When Co-administered in Healthy Adults
Key Details
Gender
All
Age Range
19 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2025-03-24
Completion Date
2025-09-07
Last Updated
2025-09-09
Healthy Volunteers
Yes
Conditions
Interventions
Epaminurad 9 mg
Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
C2406
Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
Locations (1)
Seoul National University Hospital Clinical Trials Center
Seoul, Seoul, South Korea